News + Filings Key Docs Charts Transactions Holdings Ownership
All
13F
13D/G
Other
|
|
BAYER AKTIENGESELLSCHAFT (BAYRY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/11/2022 |
SC 13G
| BAYER AKTIENGESELLSCHAFT reports a 23.2% stake in Century Therapeutics, Inc. |
| 10/15/2021 |
4
| Bayer World Investments B.V. (Former 10% Owner) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Converted 2,742,338 shares
@ $0
Converted 11,362,462 convertible preferred
@ $0
Converted 6,076,072 convertible preferred
@ $0 |
|
| 10/07/2021 |
3
| Bayer World Investments B.V. (10% Owner) has filed a Form 3 on Pyxis Oncology, Inc. |
| 06/23/2021 |
4
| BAYER AKTIENGESELLSCHAFT (10% Owner) has filed a Form 4 on Century Therapeutics, Inc.|
Txns:
| Converted 10,390,600 shares
@ $0
Converted 1,535,238 shares
@ $0
Bought 750,000 shares
@ $20, valued at
$15M
Converted 26,143,790 preferred shares
@ $0
Converted 3,862,813 preferred shares
@ $0 |
|
| 06/17/2021 |
3
| BAYER AKTIENGESELLSCHAFT (10% Owner) has filed a Form 3 on Century Therapeutics, Inc. |
| 12/03/2020 |
4
| BAYER AKTIENGESELLSCHAFT (10% Owner) has filed a Form 4 on Elanco Animal Health Inc|
Txns:
| Sold 54,500,000 shares
@ $29.8416, valued at
$1626.4M
|
|
| 12/03/2020 |
SC 13G/A
| BAYER AKTIENGESELLSCHAFT reports a 3.9% stake in Elanco Animal Health Incorporated |
| 08/03/2020 |
3
| BAYER AKTIENGESELLSCHAFT (10% Owner) has filed a Form 3 on Elanco Animal Health Inc |
| 08/03/2020 |
SC 13G
| BAYER AKTIENGESELLSCHAFT reports a 15.5% stake in Elanco Animal Health Incorporated |
| 01/30/2018 |
4
| BAYER AKTIENGESELLSCHAFT (10% Owner) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Bought 527,472 shares
@ $22.75, valued at
$12M
|
|
| 11/25/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 11/16/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 11/15/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 11/10/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 11/09/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 10/31/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 10/28/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 10/18/2016 |
3
| Bayer Global Investments B.V. (10% Owner) has filed a Form 3 on CRISPR Therapeutics AG |
| 10/17/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 10/13/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 10/12/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 10/11/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 09/21/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 09/20/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 09/16/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 09/14/2016 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material |
| 09/06/2016 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 07/27/2016 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
| 07/14/2016 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
| 07/05/2016 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
| 06/28/2016 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
|
|
|